Secretin-stimulated amylase release into blood is impaired in type 1 diabetes mellitus

Arthur L Swislocki, R. Noth, A. Hallstone, E. Kyger, C. Triadafilopoulos

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Prior studies have provided data indicating the existence of close interaction between pancreatic endocrine and exocrine function, but few clinical studies have explored this relationship in depth. We compared pancreatic exocrine function non-endoscopically in individuals with type 1 diabetes mellitus, type 2 diabetes mellitus, and normal glucose tolerant controls, to assess the importance of local insulin production to pancreatic exocrine function. Methods: The plasma amylase response to intravenous secretin challenge was measured in men with type 1 diabetes mellitus (n = 5), type 2 diabetes mellitus (n = 5), and normal controls (n = 3). Patients were characterized by their urinary excretion of c-peptide and albumin over 24 hours. Autonomic neuropathy was non-invasively assessed by measuring RR variation (with deep respiration on EKG). Results: Post-secretin amylase responses were generally absent with low baseline levels in the patients with type 1 diabetes mellitus. Patients with type 2 diabetes mellitus and controls showed similar twofold increases over baseline after secretin administration. When normal glucose tolerant and type 2 diabetic patients were pooled and compared against type 1 diabetes mellitus, the differences were statistically significant (p < 0.03). Total amylase response correlated positively, but weakly, with 24 h urinary C-peptide excretion (r = 0.507; p < 0.112), but not with glycemic control, duration of diabetes, or indices of autonomic neuropathy. Conclusions: Patients with type 1 diabetes mellitus, but not type 2 diabetes mellitus, have reduced pancreatic exocrine function, supporting the concept of a local paracrine effect of insulin on pancreatic acinar cells. Further studies are needed to determine the clinical impact of this deficiency, and whether such patients with type 1 diabetes mellitus would benefit from therapy with pancreatic enzyme supplementation.

Original languageEnglish (US)
Pages (from-to)326-330
Number of pages5
JournalHormone and Metabolic Research
Volume37
Issue number5
DOIs
StatePublished - May 2005
Externally publishedYes

Fingerprint

Secretin
Amylases
Medical problems
Type 1 Diabetes Mellitus
Blood
Type 2 Diabetes Mellitus
Insulin
Glucose
Acinar Cells
C-Peptide
Albumins
Electrocardiography
Respiration
Peptides
Enzymes
Plasmas

Keywords

  • Autonomic nervous system
  • C-peptide
  • Diabetes mellitus
  • Pancreatic exocrine function
  • Plasma amylase
  • Secretin

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Secretin-stimulated amylase release into blood is impaired in type 1 diabetes mellitus. / Swislocki, Arthur L; Noth, R.; Hallstone, A.; Kyger, E.; Triadafilopoulos, C.

In: Hormone and Metabolic Research, Vol. 37, No. 5, 05.2005, p. 326-330.

Research output: Contribution to journalArticle

Swislocki, Arthur L ; Noth, R. ; Hallstone, A. ; Kyger, E. ; Triadafilopoulos, C. / Secretin-stimulated amylase release into blood is impaired in type 1 diabetes mellitus. In: Hormone and Metabolic Research. 2005 ; Vol. 37, No. 5. pp. 326-330.
@article{70e8fe718fdd433781f07de4e12a76cd,
title = "Secretin-stimulated amylase release into blood is impaired in type 1 diabetes mellitus",
abstract = "Background: Prior studies have provided data indicating the existence of close interaction between pancreatic endocrine and exocrine function, but few clinical studies have explored this relationship in depth. We compared pancreatic exocrine function non-endoscopically in individuals with type 1 diabetes mellitus, type 2 diabetes mellitus, and normal glucose tolerant controls, to assess the importance of local insulin production to pancreatic exocrine function. Methods: The plasma amylase response to intravenous secretin challenge was measured in men with type 1 diabetes mellitus (n = 5), type 2 diabetes mellitus (n = 5), and normal controls (n = 3). Patients were characterized by their urinary excretion of c-peptide and albumin over 24 hours. Autonomic neuropathy was non-invasively assessed by measuring RR variation (with deep respiration on EKG). Results: Post-secretin amylase responses were generally absent with low baseline levels in the patients with type 1 diabetes mellitus. Patients with type 2 diabetes mellitus and controls showed similar twofold increases over baseline after secretin administration. When normal glucose tolerant and type 2 diabetic patients were pooled and compared against type 1 diabetes mellitus, the differences were statistically significant (p < 0.03). Total amylase response correlated positively, but weakly, with 24 h urinary C-peptide excretion (r = 0.507; p < 0.112), but not with glycemic control, duration of diabetes, or indices of autonomic neuropathy. Conclusions: Patients with type 1 diabetes mellitus, but not type 2 diabetes mellitus, have reduced pancreatic exocrine function, supporting the concept of a local paracrine effect of insulin on pancreatic acinar cells. Further studies are needed to determine the clinical impact of this deficiency, and whether such patients with type 1 diabetes mellitus would benefit from therapy with pancreatic enzyme supplementation.",
keywords = "Autonomic nervous system, C-peptide, Diabetes mellitus, Pancreatic exocrine function, Plasma amylase, Secretin",
author = "Swislocki, {Arthur L} and R. Noth and A. Hallstone and E. Kyger and C. Triadafilopoulos",
year = "2005",
month = "5",
doi = "10.1055/s-2005-861478",
language = "English (US)",
volume = "37",
pages = "326--330",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "5",

}

TY - JOUR

T1 - Secretin-stimulated amylase release into blood is impaired in type 1 diabetes mellitus

AU - Swislocki, Arthur L

AU - Noth, R.

AU - Hallstone, A.

AU - Kyger, E.

AU - Triadafilopoulos, C.

PY - 2005/5

Y1 - 2005/5

N2 - Background: Prior studies have provided data indicating the existence of close interaction between pancreatic endocrine and exocrine function, but few clinical studies have explored this relationship in depth. We compared pancreatic exocrine function non-endoscopically in individuals with type 1 diabetes mellitus, type 2 diabetes mellitus, and normal glucose tolerant controls, to assess the importance of local insulin production to pancreatic exocrine function. Methods: The plasma amylase response to intravenous secretin challenge was measured in men with type 1 diabetes mellitus (n = 5), type 2 diabetes mellitus (n = 5), and normal controls (n = 3). Patients were characterized by their urinary excretion of c-peptide and albumin over 24 hours. Autonomic neuropathy was non-invasively assessed by measuring RR variation (with deep respiration on EKG). Results: Post-secretin amylase responses were generally absent with low baseline levels in the patients with type 1 diabetes mellitus. Patients with type 2 diabetes mellitus and controls showed similar twofold increases over baseline after secretin administration. When normal glucose tolerant and type 2 diabetic patients were pooled and compared against type 1 diabetes mellitus, the differences were statistically significant (p < 0.03). Total amylase response correlated positively, but weakly, with 24 h urinary C-peptide excretion (r = 0.507; p < 0.112), but not with glycemic control, duration of diabetes, or indices of autonomic neuropathy. Conclusions: Patients with type 1 diabetes mellitus, but not type 2 diabetes mellitus, have reduced pancreatic exocrine function, supporting the concept of a local paracrine effect of insulin on pancreatic acinar cells. Further studies are needed to determine the clinical impact of this deficiency, and whether such patients with type 1 diabetes mellitus would benefit from therapy with pancreatic enzyme supplementation.

AB - Background: Prior studies have provided data indicating the existence of close interaction between pancreatic endocrine and exocrine function, but few clinical studies have explored this relationship in depth. We compared pancreatic exocrine function non-endoscopically in individuals with type 1 diabetes mellitus, type 2 diabetes mellitus, and normal glucose tolerant controls, to assess the importance of local insulin production to pancreatic exocrine function. Methods: The plasma amylase response to intravenous secretin challenge was measured in men with type 1 diabetes mellitus (n = 5), type 2 diabetes mellitus (n = 5), and normal controls (n = 3). Patients were characterized by their urinary excretion of c-peptide and albumin over 24 hours. Autonomic neuropathy was non-invasively assessed by measuring RR variation (with deep respiration on EKG). Results: Post-secretin amylase responses were generally absent with low baseline levels in the patients with type 1 diabetes mellitus. Patients with type 2 diabetes mellitus and controls showed similar twofold increases over baseline after secretin administration. When normal glucose tolerant and type 2 diabetic patients were pooled and compared against type 1 diabetes mellitus, the differences were statistically significant (p < 0.03). Total amylase response correlated positively, but weakly, with 24 h urinary C-peptide excretion (r = 0.507; p < 0.112), but not with glycemic control, duration of diabetes, or indices of autonomic neuropathy. Conclusions: Patients with type 1 diabetes mellitus, but not type 2 diabetes mellitus, have reduced pancreatic exocrine function, supporting the concept of a local paracrine effect of insulin on pancreatic acinar cells. Further studies are needed to determine the clinical impact of this deficiency, and whether such patients with type 1 diabetes mellitus would benefit from therapy with pancreatic enzyme supplementation.

KW - Autonomic nervous system

KW - C-peptide

KW - Diabetes mellitus

KW - Pancreatic exocrine function

KW - Plasma amylase

KW - Secretin

UR - http://www.scopus.com/inward/record.url?scp=21244471512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244471512&partnerID=8YFLogxK

U2 - 10.1055/s-2005-861478

DO - 10.1055/s-2005-861478

M3 - Article

C2 - 15971157

AN - SCOPUS:21244471512

VL - 37

SP - 326

EP - 330

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 5

ER -